Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway
Authors:
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 190, 114635
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Education (2018R1D1A1B07049009, NRF2015R1D1A1A01059738)
- Ministry of Health and Welfare (1320060)
This publication has 39 references indexed in Scilit:
- Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsJournal of Translational Medicine, 2013
- Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell propertiesJournal of Cancer Research and Clinical Oncology, 2012
- Cytoplasmic Estrogen Receptor in Breast CancerClinical Cancer Research, 2012
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivationBreast Cancer Research, 2011
- Slow-Cycling Therapy-Resistant Cancer CellsStem Cells and Development, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinationsBreast Cancer Research, 2010
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- Restoration of Tamoxifen Sensitivity in Estrogen Receptor–Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor ComplexesCancer Research, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004